Literature DB >> 6978431

Glutamine requirements for purine metabolism in leukemic lymphoblasts.

K O Raivio, L C Andersson.   

Abstract

The two pathways of purine metabolism that include glutamine-dependent reactions, purine synthesis de novo and guanine nucleotide synthesis, were studied in cultured lymphoblasts derived from patients with T cell (JM), B cell (BALL) or null cell (NALL) acute lymphoblastic leukemia (ALL). When glutamine was omitted from the incubation medium, purine synthesis de novo, measured by the incorporation of 14C-formate into purine compounds, was depressed to barely measurable rates in BALL and NALL cells, but proceeded at moderate though reduced rates in JM cells, when compared to synthesis in the presence of 2 mM glutamine. Similarly, the incorporation of 14C-hypoxanthine into guanine nucleotides was arrested at the glutamine-requiring XMP-aminase reaction in the BALL and NALL lines but not in the JM line, when exogenous glutamine was absent. The data suggest that glutamine deprivation, whether by omission from the culture medium in vitro or by glutaminase treatment in vivo, will have more profound biochemical consequences in B and null cell-derived ALL than in T All.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978431     DOI: 10.1016/0145-2126(82)90049-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  1 in total

1.  Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.

Authors:  Tra Ly Nguyen; Marie-Julie Nokin; Silvia Terés; Mercedes Tomé; Clément Bodineau; Oriane Galmar; Jean-Max Pasquet; Benoit Rousseau; Sebastian van Liempd; Juan Manuel Falcon-Perez; Elodie Richard; Elodie Muzotte; Hamid-Reza Rezvani; Muriel Priault; Marion Bouchecareilh; Isabelle Redonnet-Vernhet; Julien Calvo; Benjamin Uzan; Françoise Pflumio; Patricia Fuentes; Maria L Toribio; Abdel-Majid Khatib; Pierre Soubeyran; Piedad Del Socorro Murdoch; Raúl V Durán
Journal:  Mol Oncol       Date:  2021-02-13       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.